Share this video  

SITC 2021 | Offering surgery to treatment-naïve patients with STS

Emily Z. Keung, MD, AM, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the importance of offering surgery to patients with soft tissue sarcomas (STS) earlier in the treatment course. Currently, clinical trials in STS most commonly enrol patients that have already received multiple lines of prior therapy. By resecting the tumor earlier in the disease course, it is possible to study its characteristics and design future clinical trials that will build upon findings from the Phase II trial (NCT03307616) assessing immune checkpoint blockade (ICB) therapy in patients with STS prior to surgery that demonstrated the positive prognostic impact of immune infiltrates in STS. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.